Allterum Therapeutics

Executive Summary

Allterum Therapeutics is a private biotechnology company headquartered in San Diego, CA, focused on developing antibody-based biologic therapies for relapsed/refractory hematologic malignancies, particularly T-cell acute lymphoblastic leukemia (ALL) and B-cell malignancies. Founded in 2018, the company targets patients with limited effective standard options, addressing a significant unmet medical need. While specific pipeline programs are not publicly disclosed, Allterum's approach leverages antibody engineering to improve targeting and reduce toxicity. The company operates in a competitive space but its niche focus on relapsed/refractory populations may offer differentiation. Given its early stage, Allterum's progress depends on advancing preclinical candidates into clinical development and securing partnerships or funding to support trials.

Upcoming Catalysts (preview)

• Q1 2027IND filing for lead candidate30% success
• Q4 2026Preclinical data presentation at major conference50% success
• Q2 2027Series A or B financing round40% success